Introduction: Leptomeningeal involvement in adult acute myeloid leukemia (AML) from onset is infrequent (5-7%). Treatment in such cases includes repeated doses of intrathecal (IT) chemotherapy via lumbar puncture or intraventricular administration through an Ommaya reservoir. Liposomal cytarabine (DepoCyte®), a sustained-release cytarabine formulation, is a new drug that must be administered intrathecally at a dose of 50 mg in application to lymphomatous meningitis. Although the drug has not been indicated yet for leptomeningeal involvement in adults with AML, its application in this setting seems reasonable. We present our experience with an adult female patient presenting AML-M5b with meningeal infiltration, where the drug was administered on a compassionate use basis following the obtainment of informed consent. Clinical case: An 18-year-old woman with AML M5-b (CD56 +, karyotype +8 an reordering of gene MLL -11q23) with symptomatic leptomeningeal infiltration in the form of chin dysesthesia and 6 blast cells in CSF. Treatment was provided in the form of systemic chemotherapy (CT) idarubicin 12 mg/m² and cytarabine 200 mg/m² in continuous perfusion per 7 doses on two occasions, achieving complete remission after the first cycle (minimal residual disease, MRD = 0.35%). In coincidence with systemic treatment, two doses of IT triple therapy (MTX 12mg/ ARA-C 30 mg/Metilprednisolone 10 mg) proved unable to clear blast cells in CSF, and 5 doses of liposomal cytarabine were administered every 15 daysfollowed by disappearance of blast cell infiltration after the first dose, with improvement of the neurological symptoms when complete response was observed. After this first shot, 4 more cycles of liposomal cytarabine were administered and still the CSF obtained was normal. The patient developed postpuncture headache as a complication of IT therapy. Finally an allogenic transplantation from a histocompatible female sibling has been performed in complete response situation. Conclusion: The present case illustrates the efficacy of liposomal cytarabine, by eliminating blast cell infiltration in CSF following the first IT dose -this situation being maintained until the time of bone marrow transplantation. The reduction in number of lumbar punctures improves patient quality of life and minimizes the risk of contamination. Postpuncture headache was the only side effect recorded.
Severe aplastic anaemia
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Factors of predisposition to aplastic anaemia in Russian population E. Khamaganova, L. Murashova, E. Mikhailova, Y. Zaretskaya Research Centre for Hematology (Moscow, RUS) Many autoimmune diseases are associated with HLA alleles, and such relationship also has been reported for aplastic anemia (AA). The presence of particular HLA alleles likely allows for preferential presentation of particular peptides, perhaps derived from autoantigens, to specific T cells, driving the autoimmune process. AA is a severe hematological disorder with a high mortality. The susceptibility to the development of AA is strongly associated with genes in the major histocompatibility complex (MHC or HLA in human beings). Immunogenetic studies have been reported about a strong association between AA and antigen HLA-DR2 (DRB1*15) in different populations. The objective of our study was the examination of the distribution of HLA class I and II alleles in 34 russian AA patients, which were typed in our laboratory between 1996 and 2004 years. The controls were 438 donors of Russian Bone Marrow Donor Registry. Methods: HLA class I (HLA-A, -B and -Cw loci) typing was made by standard complement-dependent lymphomicrocytotoxic test using 2 serum sets: Gisans (SanktPetersburg, Russia) and One Lambda (USA) simultaneously. The preparation of DNA from peripheral blood was made by Promega DNA purification kit (USA). HLA class II (HLA-DRB1 and -DQB1 loci) typing in all cases was made by PCR with sequence specific primers (Dynal, Norway or DNA technology, Russia). HLA antigens frequencies were compared by exact Fisher test. The strength of association between HLA-antigens and disease was determined by the evaluation of relative risk (RR), etiological fraction (EF) and preventive fraction (PF). The results show that the most frequent specificities in AA patients were DRB1*15 (50.0% vs.18.8% in controls, p<0.01, RR=4, EF=0.37 ), DRB1*04 (37.5% vs. 20.1% in con-trols, p<0.05, RR=2.7, EF=0.23) and DQB1*06 (64.7 vs. 42.9 in controls, p<0.05, RR=2.7, EF=0.41). Conclusion: DRB1*15, DRB1*04 and DQB1*06 are the factors of predisposition to the development of AA in russian population. DRB1*15 is the most significant risk factor for this disease.
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CD34+ positively selected cells, enriched with CD3+ cells, for the graft failure treatment in paediatric patients with aplastic anaemia P. Trakhtman, D. Balashov, I. Schipicina, Z. Dishlevaja, U. Svortcova, O. Blagonravova, E. Scorobogatova, A. Maschan Institute for Paediatric Haematology (Moscow, RUS) Allogeneic transplantation of hematopoietic stem cells is a treatment of choice for patients with severe acquired aplastic anemia (SAA) that have an HLA-identical donor. This treatment has been able to cure 80-90% of young SAA patients. Meanwhile, early and late graft failure still remains a major problem, compromising the survival of these patients. The intensification of preparative regimen and the use of high doses of stem cell has led to further reduction of the graft failure rate, but the problem is uncertain until now. Moreover, deep immunosupression associated with second transplant procedure and GVHD onset, may further decrease the survival rate of these patients. We report two pediatric SAA patients with transient engraftment after allogeneic bone marrow transplantation (BMT), compromised with acute GVHD. They received a CD34-selected stem cells boost from the same donor enriched with CD3+ cells and achieved full donor chimerism and stable hematopoietic reconstitution. Both patients suffered from GVHD reappearance and were successfully treated with steroids. Hence, the use of large numbers of CD34-positively selected stem cells with the addition of CD3 cell may be additional alternative for the patients after stem cell transplantation with mixed chimerism and graft insufficiency at risk for GVHD reactivation.
Autoimmune diseases
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Acute promyelocytic leukaemia after high-dose chemotherapy and autologous stem cell transplantation in a patient with multiple sclerosis I. Lisukov, A. Kulagin, S. Sizikova, I. Kruchkova, O. Malysheva, V. Denisova, A. Gilevich, V. Kozlov Institute of Clinical Immunology RAMS SB (Novosibirsk, RUS); Novosibirsk State Medical Academy (Novosibirsk, RUS) Introduction:
High-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) has been proposed as an effective therapy for patients with secondary progressive multiple sclerosis (SPMS). Despite of low transplant-related mortality risk, late effects may become more significant causes of morbidity and mortality. Here we report a MS patient who developed acute promyelocytic leukemia after ASCT. Case report: The patient was a 42 year old female suffered from MS since 1989. SPMS was diagnosed in 1998. She was treated with methylprednisolone with little effect. In 2001 she was severely disabled with EDSS 6.5 and gain of 2.5 EDSS point during the past year. Multiple brain lesions with a single gadolinium (Gd) enhancing lesion were present on MRI scans. After giving informed consent she was enrolled in a phase I/II clinical study according to EBMT protocol. Peripheral blood stem cells were mobilized by CY and G-CSF. The conditioning regimen was BEAM followed by horse ATG. ASCT (15x106 CD34+ cells/kg) was performed in March 2001. Neutropenic fever, serum sickness and transient progression of bladder dysfunction developed in early post-transplant period. Neurological stabilization with no Gd-enhancing lesions on MRI was during the first year post transplant. At 12 months after ASCT a worsening of tetraparesis developed. EDSS advanced from 6.5 to 7.0. Two Gd-enhancing lesions were present on MRI. She was treated with methylprednisolone followed by 2 single doses of mitoxantrone (10 mg/m² at 14 and 18 months after ASCT) with a slightly neurological improvement. She remained neurogically stable during next 2 year. Her blood count was normal during this follow-up period. At 43 months after ASCT she developed anemic symptoms, fever and mucosal and skin hemorrhage. She was taken urgently to a local hematological department, where the severe pancytopenia was detected. Bone marrow aspiration found 8% of blast cells and 78% of promyelocytic cells. Cytogenetic study did not perform. Patient died on second hospital day due to cerebral hemorrhage. Conclusion: In this observation not all of the diagnosis criteria for therapy-related leukemia induced by HDCT and possibly mitoxantrone are present. Nevertheless this case stresses the need to further evaluate the long-term risk of ASCT in patients with MS.
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Characterisation of mesenchymal stem cells in systemic sclerosis R. Saccardi, S. Urbani, A. Bosi, M. Cinelli, S. Guiducci, I. Miniati, A. Tyndall, M. Matucci Cerinic Ospedale di Careggi (Florence, I); Felix-Platter-Spital (Basel, CH) Systemic sclerosis (SSc) is a chronic disorder of unknown etiology. The pathology of SSc shows an involvement of three major systems: endothelial, immune and connective. Excessive deposition of collagen and other extracellular components (fibrosis) in the skin and in visceral organs is one of the hallmark of the disease. The pathology of fibrosis in SSc demonstrates excessive fibroproliferation and deposition of various extracellular matrix proteins by mesenchymal cells.
Haematopoetic Stem Cells Transplantation (HSCT) has been proposed for patients not responding to conventional treatments. Mesenchymal stem cells (MSCs) are progenitors of multiple mesenchymal lineages and can generate a wide range of fully differentiated connective tissues such as cartilage, bone, fat, fibrous tissue and myelosupportive stroma. We investigated some basic biological properties of MSCs collected from the Bone Marrow (BM) of SSc patients diagnosed with the diffuse subset of SSc and BM cells from healthy donors were used as controls. CFU-F (Colony Forming Units-Fibroblastoid) mean number (+/-SEM)/10E6 nucleated seeded cells in SSc patients (n=4) and healthy donors (n=5) were 249+/-79 and 58+/-30 respectively (p<0.05). MSCs were grown in plastic flasks at standard conditions. At the fourth passage the mean fold expansion in patients and donors was 2204+/-248 and 55+/-37 respectively (p<0.05). The phenotypic expression of some haematopoietic and mesenchymal markers (CD34, CD14, CD45, HLA-A B C, HLA-DP-DQ-DR, CD29, CD44, CD73, CD90, CD105, CD166) was analysed by flow cytometry at the first passage (n=6). All cells showed a typical mesenchymal phenotype, but expression of CD29, CD44, CD166, HLA A B C and HLA DP DQ DR was significantly different in patients and healthy donors respectively. Data (mean+/-SEM) are reported in the table (*p<0.05). Pathophysiology of SSc is still unclear and involves different tissues. The finding of an abnormal pattern of biological markers in MSCs, collected from patients affected by a rapidly aggressive subset of the disease, suggests that MSCs are modified in respect to controls. This observation may indicate that, in SSc, mesenchymal progenitors of the bone marrow compartment are modified. Monitoring of biological properties of MSCs in SSc might play a role in the evaluation of the efficacy of HSCT in these patients.
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Autologous stem cell transplantation with T-cell depletion for refractory chronic autoimmune thrombocytopenic purpura E. Elli, A. Larocca, P. Perseghin, M. Dassi, D. Belotti, E. Terruzzi, M. Parma, E. Pogliani Ospedale S. Gerardo (Monza, I) Background: Severe chronic autoimmune thrombocytopenic purpura (AITP) refractory to conventional treatments can be treated with myelo-and immuno-suppressive chemotherapy followed by autologous peripheral blood stem cell (PBSC) transplantation. T-cells depletion of the graft is needed to reduce autoreactive clones. In fact T lymphocytes may initiate and maintain immune recognition of autologous platelets (PLT) and stimulate B lymphocytes to produce anti-PLT antibodies. Theoretically, autoreactive T lymphocytes collected in PBSC graft could re-establish autoimmunity, so immunologic purging of T-cells is required as a fundamental condition for the favorable success of transplantation. We report a 60 years old female patient affected by AITP, refractory to conventional therapy: steroids, intravenous immunoglobulins, splenectomy and immunosuppressive agents as cyclophosphamide, cyclosporine, vincristine, azathioprine. Therefore she was submitted to T-cell-depleted autologous transplantation two years after the onset of the disease. Methods: PBSC were mobilised with cyclophosphamide (2,5 g/m²) and G-CSF (10 microg/Kg/die) and collected by a single leukapheresis. CD34+ positive immunomagnetic selection (CliniMACS, Miltenyi) allowed to select stem cells and to remove T-cells from the graft. The final dose of CD34+ cells was 7.2 x 10 6 /Kg, and the residual dose of CD3+ cells in the graft was 1 x 10 5 . Conditioning regimen was Melphalan 100 mg/m². Results: Neither major adverse events nor infection were observed during and following the transplant phase. Mild epistaxis and mouth bleeding were controlled by PLT transfusions during pre-engraftment phase. Neutrophil recovery (>500/mm³) was observed from day +9 and PLT recovery (>20000/mm³) from day +18. Asymptomatic CMV reactivation was documented only on day +29 (CMV antigen:12 cells/200.000 WBC) and not confirmed during successive week controls. After 80 days of follow-up the patient shows a partial response with a stable PLT count around 50.000/mm³ despite an initial reduction immediately after the engraftment. The patient is currently treated only with antiviral and anti-P. Carinii profilaxis. Conclusion: Autologous T cell-depleted PBSC transplantation may be considered a feasible therapeutic option in refractory severe AITP, so as for other refractory autoimmune disorders, but larger studies are still required to demonstrate the percentage and the durability of the remission and the real risk/benefit profile.
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Monoclonal anti CD20 antibody rituximab (Mabthera) in the treatment of autoimmune cyclical neutropenia -case report B. Georgievski, A. Stojanovic, N. Siljanoski, L. Cevreska, S. Genadieva Stavric, Z. Stojanoski, I. Panovska, A. Pivkova, S. Trajkova, S. Balkanov, O. Karanfilski Clinical Center (Skopje, MK) Autoimmune cyclical neutropenia is a rare syndrome with periodically severe but temporary neutropenia (Ne < 2.0x10 9 /L), with occurrence of 3-4 weeks, but not rarely in 2 week or 5 week intervals. Antibody with specificity for the neutrophils has been demonstrated in a number of different neutropenic disorders. In the underlying disorder the antibodies are directed to one of the specific granulocyte antigens. Rituximab (Mabthera) is a chimeric antibody that recognizes the CD20 antigen expressed by B cells; therefore this treatment option has been evaluated in the therapeutic approach of autoimmune diseases. We present a case of 66 years male patient admitted at our department in August 1998 with leucopenia WBC 1.5x10 9 /L and clinical signs of infections that have been registered on several other intermittent occasions (2-3weeks) since 1985. In 1995 a surgical procedure has been preformed (hemicolectomia) with patohystological findings for Crohn's disease and until 1998 patient has been treated with Salofalksalazoprim. The treatment was discontinued because of leucopenia and suspicion of iatrogenic neutropenia. In august 1999 bone marrow biopsy revealed reduction of granulopoesis and absence of neutrophils in the peripheral smearagranulocytosis. Immunological investigations revealed increased polyclonal IgG 28,5g/L, IgA 10,8 g/L, IgM 4,7 g/L. Laboratory tests for Lupus erithematodes were negative. In February 2001 in "St.George's Hospital" in London other investigations were provided and showed positive indirect granulocyte immunofluorescence test (IgM). The patient had continuously intermittent neutropenia every 2 weeks, presented with febrile episodes and infections, treated with G-CSF (Neupogen) until increase of granulocytes up to >1.0x10 9 /L. In the beginning of august 2004 it was decided to start treatment with Rituximab (Mabthera), an infusion with standard single agent 375mg/m² weekly for 4 weeks. After four infusions WBC reached normal levels, after which the treatment continued with every two weeks infusion of monoclonal antibody in duration of 2 months and now once a month. At the end we can conclude that B cells play a central role in the autoimmune process and Rituximab treatment has been used in patients with autoimmune neutropenia, since it is characterized by formation of antigranulocyte auto-antibodies that cause destruction of granulocytes. Further studies will define optimal role for Rituximab treatment of autoimmune disease.
Chronic leukaemia
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Allogeneic and autologous stem cell transplantation for chronic myelogenous leukaemia M. Mistrik, M. Hrubisko, E. Demeckova, E. Bojtarova, P. Kotoucek, B. Czako, K. Nachtmanova, J. Chabronova, M. Gubkova, M. Avramovova, D. Jankovicova, J. Martinka, M. Kusikova, D. Stemnicka, A. Batorova, M. Skrakova, D. Pavlíkova, D. Cupanikova, E. Fehervizyova Medical Facutly Comenius University (Bratislava, SVK) ; National Transfusion Service (Bratislava, SVK) Allogeneic hematopoietic stem cell transplantation (SCT) is an effective therapy for younger patients with chronic myelogenous leukemia (CML). Introduction of SCT in our clinic offers its availability for patients in our country. However, only about one third of patients has a HLA-identical related donor. Unrelated donor SCT can cure CML as well, but is associated with a high risk transplant related mor-tality. Autologous SCT is a non-curative alternative with significant tumor mass reduction. Patient and methods. A retrospective analysis of allo and autotransplanted patients: 87 allotransplanted patients [74 in first chronic phase(CP), 13 with advanced phase(AP)], age 16 -59 yrs (median 36 yrs), 52 males and 35 females, with 90 SCTs (3 patients with 2nd SCT), 85 from HLA-ident. sibs and 5 from unrelated donors; 20 autotransplanted patients (11 in first CP and 9 with AP), age range 20 -57 yrs (median 42 yrs), 15 males and 5 females. Conditioning regimen was based on busulphan both for allo and auto SCT. Results. AlloSCT: till October 31, 2004, 51 of 87 patients are alive without signs of disease, in a range 1 -173 months, median time of observation 31 months, 3 yrs disease free survival probability 59% (64% for CP, 31% AP). 36 patients died 1-70 months (median 5) after SCT. Autotransplanted patients as of October 31, 2004, 9 of 20 are alive (7 of 11 with CP and 2 of 9 with AP), all are Ph positive. Overall long term survival probability is 41% (58% in CP, but 0 in AP!). Conclusion. Allogeneic SCT from HLA -identical siblings has significant but acceptable risk of peritransplant morbidity and mortality, and high curative potential. Autologous SCT for CML is associated with much lower peritransplant mortality risk, but there is inevitable CML relapse incidence. Nowadays, autoSCT offer palliation and more effective in vivo purging before stem cell harvest and more effective maintenance therapy may lead to better long-term results.
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Increased frequency of MICB0104 allele in patients with chronic myelogenous leukaemia in Japanese population N. Sato, N. Takahashi, T. Nagamura, S. Asano, A. Tojo University of Tokyo (Tokyo, JP) Although the chimeric protein of BCR-ABL has been shown to be casually related to the development of chronic myelogenous leukemia (CML), little is known concerning other factors suppressing or accelerating the leukemogenic process. One possibility would be immune system including adaptive and innate immunity. Recently, natural killer cells (NK cells) have been recognized as effectors in hematological malignancies. We started studies on genotypes of various genes related to NK cell functions in patients with CML. Among 54 patients with CML and 86 controls, major histocompatibility complex class-I-chain-related gene B (MICB) allele 0104 was statistically associated with CML (p<0.05), suggesting that MICB 0104 allele is a risk factor for CML (odds ratio (OR) =2.26 ; 95% confidence interval (CI): 1.08-4.61). Individuals with at least one 0104 allele are at a risk for CML compared with those without 0104 allele (p<0.05) (OR= 2.57 ; 95% CI: 1.15-5.75). Since MICB is a ligand for activating receptor of NK cells and co-activator of CD8+T cells, the results suggest that cellular immunity including NK cells and CD8+ T cells may influence CML leukemogenesis. This may also suggest that we should much consider NK cells in the case of donor lymphocyte infusions after stem cell transplantation for CML.
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Outcome of patients with CML/Ph positive ALL who received imatinib mesylate before or after allogeneic stem cell transplant -a single-centre experience
Purushothaman Hospital Kuala Lumpur (Kuala Lumpur, MYS)
Allogeneic stem cell transplant(SCT)is the curative treatment in CML. Imatinib mesylate(STI) is effective in all stages of CML, with the best response if started in the chronic phase. We present our single-centre experience with CML and Ph positive ALL treated with allogeneic SCT and STI. Transplants were done between January 2000 and February 2004. 8 patients were treated: 4 males, 4 females. The median and mean ages were 27 and 20 years respectively (range 14-38 years. 7 patients had CML(3 in chronic phase,3 in acceleration,1 in blast crisis and 1 ALL). As of September 2004,7 patients were alive,2 with relapsed CML and 1 patient died of blast crisis. 5 patients (62.5%) are in complete cytogenetic remission (CCR).3 were transplanted in chronic phase,1 in acceleration and 1 ALL.The mean duration post SCT was 18.8 months, median 14 months. 3 patients received STI pre SCT. STI was stopped prior to SCT and 2 patients were in remission post SCT and no longer on STI. 1 had STI restarted 4 weeks post SCT. 4 patients received STI for relapse post SCT after failing donor lymphocyte infusion(DLI). 3 were transplanted in acceleration and 1 in blast crisis. The 3 in acceleration had cytogenetic relapse at mean of 4.6 and median of 3 months (range 3-8 months) post SCT. All 3 failed DLI. They were put on STI (1 had combination with interferon-a(IFN)). 1 had CCR with STI plus IFN. This patient was started on STI 8 months post DLI. 1 achieved hematologic response. The other patient failed to respond but is still alive in blast crisis 3 years post SCT. 2 patients at high risk started STI preemptively 4 weeks post SCT. 1 had ALL. He remained in CCR for 1 year post SCT but relapsed in the skull and chest wall. He achieved remission with DLI and is still alive at 2 years. The other was in refractory myeloid blast crisis. She is 9 months post SCT in CCR and is planned for prophylactic DLI. Use of STI pre and post SCT appears safe without significant toxicity. There was no engraftment problems or hepatic toxicity. The patients given STI preemptively post SCT could only tolerate 400mg because of low counts. They had nausea and vomiting which may be confused with graft versus host disease. Patients who relapse in advanced phase responded dismally. This suggests the need for close molecular monitoring or preemptive use of STI post SCT in high-risk cases.
In CML patients who relapse in the chronic phase post SCT and fail DLI, STI is a viable treatment option.
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Complete cytogenetic response in patient with relapse of chronic myeloid leukaemia treated with glivec after second allogeneic stem cell transplantation M. Elez, D. Stamatovic, L. Tukic, B. Todoric-Zivanovic, B. Balint, V. Glavicic, L. Simic, L. Ristic, M. Malesevic Military Medical Academy (Belgrade, CS) Treating relapses of chronic myeloid leukemia (CML) after the allogeneic bone marrow transplantation (BMT) is still controversial. Donor lymphocyte infusion (DLI) and specific inhibitor tyrosin-kinase Glivec have showed progress in solving such problems. We would like to present course of CML-Ph+ patient (pt) who has reached complete cytogenetic remission with Glivec in curing the relapse after the DLI and secondary allogeneic peripheral stem cell transplantation (PSCT). CML-Ph+ was diagnosed in 13 years old boy on the March 1993. Both clinical and hematological remission were achieved with Hydroxyurea after 8 months. In December 1993. an allogeneic transplantation of ''unmanipulated'' bone marrow from the HLA-DR compatible brother was done. Conditioning regimen and immunosuppressive therapy for the graft versus host disease (GvHD) prophylaxis were standard. Accepting allo graft was in due time and we have not verified either acute (a) or chronic (c) GvHD. Complete clinical, hematological, cytogenetic and molecular remission have sustained for 34 months. In September 1996. we have noticed first cytogenetic (t(9;22)) and than hematological relapse at the level of chronic phase. Considering the fact the recombinant IFN-a during 3 months was without response, pt has received 3 escalated doses of DL (2,6x10 7 , 4,1x10 7 and 4,2x10 7 ) through the period from 3 to 8 weeks, taken from same donor in the hematopoietic ''steady state'' conditions. First two doses were unfrozen and the third one was previously cryoconservated. Fifteen days after the third DLI severe pancytopenia has occurred and after that even bone marrow aplasia was proved with biopsy and myeloculture. Using the conditioning regimen with antithymocyte globulin (ATG), pt has received suspension of peripheral stem cells mobilized from the original donor in May 1997. after five day course of G-CSF (5mcg/kg BW). There were 5,3x10 8 MNC and 15,4x10 6 CD34+ cells in the PSC suspension. Allo graft acceptance was registrated on the +9 day. There was no GvHD prophylaxis and pt was in perfect clinical, hematological, cytogenetic and molecular remission without any sign of neither a nor c GvHD for 67 months till December 2002. when we have diagnosed relapse. Treatment was continued with Glivec and 7th month after the beginning with specific tyrosin-kinase inhibitor therapy, complete cytogenetic response was achieved and pt is still in stable clinical, hematological and cytogenetic remission.
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Purging in vivo with campath-1H and autologous transplantation in chronic lymphocytic leukaemia nonresponding to fludarabine: a case report L. Pezzullo, O. Finizio, L. Bene, S. Rocco, B. Casale, C. De Rosa, V. Mettivier A.O.R.N. A. Cardarelli (Naples, I) Recent observation suggest that monoclonal antibodies can have might a role in lymphoprolyferative disorders, the prognosis for not responder patients at fludarabine is bad, and high dose chemotherapy with autologous bone marrow transplantation can check better and for a longer time the disease.
Case report: 48 years-old man with diagnosis of chronic lymphocytic leukaemia (CLL) stage IV B in November 2001. Received 6 cycles of fludarabine e.v. getting a haematological partial remission but not nodal, for such the patient received other two cycles of chemotherapy and in December 2002 therapy with Campath-1H (30 mg s.c. for 3 days the week for a total dose of 313 mg) to start. Medullary immunophenotype before campath it showed an infiltration (cells CD5/CD19+) of 8%, at after therapy with Campath such marrow infiltration was 1,9%, while smaller nodal answer has been. In March 2003 the patient received therapy with high dose ciclophosphamide (7 g/m²) and G-CSF for mobilization CSP. The patient in week mobilization received other 90 mg of Campath and with 2 leucoapheresis picks up 5x106 of CD34/Kg, harvest showed a 0.5% infiltration and lymphomegalies were completely regress. In April 2003 the patient has been conditioned according to BEAM scheme and has been infused with 3x10 6 CD34/Kg. From day +1 at +5 have the patient received other 90 mg of campath s.c. Has not been late effect during hospitalisation and hematological recovery (n>500 and Plts> 20000) has been documented in the day + 16. At day +30 medullary control has underlined lymphomegalies. Hematologic recovery in the patient has been slow (at day + 60 Plts: 28000) and has needed blood support (1 blood bag weekly). Infectious episodes are not documented and continous prophylaxis with Bactrim, itraconazolo and valaciclovir has effected. At +19 months after transplantation the patient is in CCR and medullary infiltration (CD19/CD5+) is 0%, and TC not lymphomegalies here observed. In conclusion, is result in getting after bone marrow transplantation, for complete remission in a patient with CLL to bad prognosis. For evaluation of long-term answer is necessary a longer follow-up and this treatment scheme could be useful in first line treatment in patients with bad prognosis. Thirty-eight patients with B-CLL were analysed in this study: 23 at low risk stage, 9 at intermediate risk stage, and 6 at high risk stage, according to the Rai modified classification, chemotherapy naïve. Circulating Vdelta1 T lymphocytes from these patients were increased, proliferated in vitro and produced TNFalfa or IFNgamma in response to autologous B cells. These gammadelta T cells were cytolytic against the murine mastocitoma P815, upon engagement of either TCR or NKG2D; however, they did not kill resting autologous tumor B cells, which lacked the MHC-related MIC-A antigen and expressed low levels of the UL16-binding-proteins (ULBP) 1 and 3 and undetectable ULBP2 and 4. These molecules are all reported ligands for gammadelta T cells that recognizes them via the NKG2D receptor. Of note, the Vdelta1 T cell subset could lyse autologous B-CLL when transcription and expression of MIC-A and ULBP1 or upregulation of ULBP3 was achieved upon exposure to trans-retinoic acid (ATRA). Interestingly, preliminary histochemical analyses on bone marrow or lymph node specimens from two CLL patients, provide evidence for the expression of ULBP3 on neoplastic B lymphocytes. Interestingly, in six patients displaying a low number of circulating Vdelta1 T cells, and undetectable ULBPs, the disease progressed in the last year, at variance with patients with high Vdelta1 T lymphocytes and detectable/inducible ULBP3. Moreover, in all these patients leukemic cells were CD38+ and the IgVH were unmutated.
R1243 Expression and recognition of MIC-A and ULBP3 in B-
Moreover, soluble MIC-A was detected in the serum of these patients, but not in patients with stable disease.
Haematoglobinopathy
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First report from Lebanon on allogeneic haematopoietic stem cell transplantation in class III beta thalassaemia major A. Ibrahim, T. Jisr, S. Muakkit, R. Jalloul, L. Abs, G. Nsouli, E. Fadel, A. Mugharbil, N. Yassin Makassed Hospital (Beirut, LBN) Beta-thalassemia major is a common genetic disease in Lebanon. Although prenatal diagnosis has been recently developed to reduce the incidence of the disease, still significant children are born each year with thalassemia major. Although allogeneic hematopoietic stem cell transplantation is considered as a curative treatment for beta thalassemia major, still this procedure is costly and risky especially in developing countries. We present the first report on allogeneic hematopoietic stem cell transplantation in beta thalassemia major in Lebanon. Nine allogeneic transplants were performed for 8 patients at Makassed General Hospital-Beirut from 9/99 to 9/04. Median age was 5 years (5-7). There were 6 females and 2 males. All the patients were at class III according to Pesaro criteria. All the donors were HLA fully matched siblings and the hematopoietic graft was bone marrow. Conditioning regimen consisted of Busulfan (16 mg/kg) and Cyclophosphomide (150-200 mg/kg) in 3 cases. Anti lymphocyte globulins were added in 6 cases (5 patients). All the patients received Cyclosporin A and short methotrexate as GVHD prophylaxis. Major complications after transplantation were limited. Acute GVHD (grade 4) occurred in one patient who died of this complication on day 37. Severe transient hemorrhagic cystitis occurred in another patient. One patient suffering from a late graft failure received a second graft from the same donor 50 months following the first transplant. With a median follow-up of 43 months, 7 patients are alive including 5 with donor -derived normal hematopoiesis.
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Use of allogeneic blood in family donors of children with beta thalassaemia major -single-centre experience S. Samarasinghe, M. Cummins, M. McCloy St Marys Hospital (London, UK) Introduction: Stem cell transplantation (SCT) is the only curative option for beta thalassaemia major (BTM). With HLAidentical family donors, most data relates to the use of bone marrow as the source of stem cells. Traditionally, high cell doses are desirable (>4x10 8 MNC/kg) to ensure engraftment. However there is often a weight discrepancy between donor and recipient. With concerns surrounding viral/prion exposure of healthy donors, it is important to devise strategies avoiding allogeneic red cell transfusion (ART). Autologous predeposit is an option but can be technically difficult in small children and stringent EU regulations relate to banking facilities. Methods: a retrospective clinical review of chldren with BTM undergoing SCT was performed examining data relating to donor characteristics, BM harvest, use of ART and engraftment. Results: 18 children with BTM underwent allogeneic SCT between April 2001-July 2004, with median age 8.4yrs (range 2.25-13.25yrs). Median weight was 20.4kg (range 10.3-33.5kg). Donors' median age was 6.75yrs (range 2-28.4yrs); of these 10 had BT trait. Median donor weight was 24kg (range 10.5-60kg). Median volume of BM harvested=16mls/kg (range 4.3-47 ml/kg). 2 donors underwent 2 harvests. 6/18 donors received ART; 1 adult donor received an autologous unit. 5/6 who received ART had >20mls/kg harvested, 1/6 had 16mls/kg harvested. 
Inborn errors of metabolism
R1246 Allogeneic BMT followed by substrate deprivation therapy with N-butyldeoxynojirimycin in a child with Tay-Sachs disease J.F.M. Jacobs, M.A.A.P. Willemsen, J.J. Groot-Loonen, R.A. Wevers, P.M. Hoogerbrugge University Medical Center Nijmegen (Nijmegen, NL)
Introduction: Tay-Sachs disease (GM2 gangliosidosis) is a lysosomal storage disorder caused by beta-hexosaminidase A (Hex-A) deficiency, which leads to severe and progressive neurological damage. BMT has been used successfully as treatment strategy in some storage disorders. GM2 gangliosidosis mouse models demonstrate that after BMT donor-derived metabolically competent cells infiltrate the CNS leading to delayed onset of symptoms and prolonged survival. Further enhancement of survival has been reported in mice receiving a combination of substrate deprivation therapy (SDT) and BMT. To our knowledge data on the effects of BMT in children with Tay-Sachs disease are lacking. Patient: A three-year-old girl was diagnosed with Tay-Sachs disease with minimal clinical symptoms, after the same diagnosis was made in her symptomatic older sister. Pre-BMT conditioning consisted of busulfan, cyclophosphamide and ATG. She received T-cell depleted marrow from an HLA identical unrelated donor. Ciclosporin-A (CsA) was given as GvHD prophylaxis. Follow-up is 2.5 years. Results: Hex-A levels in leukocytes increased initially to donor levels and decreased to a steady level of 30% of controls for the last 1.5 years, indicating stable mixed chimerism. The enzyme levels in serum increased to 10% of controls, indicating release of enzyme into serum. Shortly after BMT, rapid progression of neurological symptoms occurred (MRI, EEG and neuro-psychological tests). Some neurological symptoms partially improved after CsA was stopped, suggesting that CsA had contributed to the neurological deterioration at that time. Experimental SDT with Nbutyldeoxynojirimycin was started 1.5 years after BMT and given during 12 months. No adverse effects of this drug were observed. During the last year (under SDT) further neurological deterioration in line with the underlying disorder became evident.
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Conclusion: BMT followed by SDT in our patient with early stage of Tay-Sachs disease resulted in Hex-A enzyme levels in leukocytes and serum of 30% and 10% of normal levels respectively. Partially reversible neurological deterioration occurred shortly after BMT, with short term stabilization thereafter. Despite additional SDT neurological deterioration became evident during further follow-up. In our patient with Tay-Sachs disease, BMT followed by SDT seemed without beneficial effect on the course of the disease. Malignant lymphoma(ML) is the third most common pediatric cancer (6 %) in South Korea. Non-Hodgkin lymphoma(NHL) accounts for 90 % of ML. Patients(pts) with aggressive NHL have a poor prognosis and the outlook remains poor. We evaluate the outcome of poor-risk NHL treated with high-dose chemotherapy and AutoSCT. Between Jun 1997 and Apr 2004, a selected group of 31 children were considered as AutoSCT candidates for folling reasons: primary refractory disease in 3, advanced stage with high-risk in 16, relapse after front-line therapy in 12 Pts. All have had Ann Arbor Stage III(11 pts) or IV(20 pts) NHL. Stem cells were obtained from mobilized peripheral blood in all pts without purge. Carmustine containing preparative regimens were given in 23 pts(74.2 %). Three pts received total body irradiation(TBI) containing regimen(TBI/cyclophosphamide/etoposide). Twenty-nine of 32 pts were in complete remission before AutoSCT. Major extramedullary toxicity after AutoSCT been limited more than grade III mucositis in 3 pts and veno-occlusive disease in one patient. After autoSCT, complete remission has been noted in 20 pts, partial remission in one patient, no response in 2 pts and progressive disease in 2 pts. The 5-year overall survival rate was 64.4 %. Our report underlies the difficulties encountered in retrospective analyses. Our results confirm that high-dose chemotherapy with AutoSCT is associated with a durable survival in a remarkable proportion of children with poor-risk NHL. Proper preparative regimens with prospective study shoul increase outcomes further. The importance of genetic factors in the etiology of Hodgkin Lymphoma (HL) and Chronic Lymphocytic Leukemia (CLL) has been suggested by family and population studies (standardized incidence ratio -SIR-for HL 1,15 and for NHL 1,71, considering entire population of first-degree relatives). We here report a familiar recurrence of lymphoproliferarive disorders in a patient undergoing allogeneic HSCT, his sibling donor and their mother. In 2002, a 44 years-old patient was diagnosed and treated in our Hospital for an B-Prolymphocitic Leukemia (CD 20+,Cd19+,CD5-,CD23-) involving Bone Marrow, multiples nodes, liver and spleen. After 3 cycles of Fludarabina, Mytoxantrone and Cyclophosphamyde a partial remission was obtained. Due to the High Risk characterisctics of the disease, the patient was treated with Hematopoietic Peripheral SCT from his healthy HLA-identical brother., after mobilization with G-CSF. Transplant protocol consisted on reduced Intensity Conditioning regimen (Thiotepa, Cyclophophamide and Fludarabine) and GVHD prophylaxis with CSA and MTX. Complete hematological remission was obtained and full chimerism is still mantained at 26 months l follow-up. After 2 year from HSC donation, In February 2004 the 56 years-oldsibling donor developed a scapular skin lesion (4cm x 3cm x 1,5cm). The histology showed an infiltration of lymphoid large cells CD20+,CD10+,CD3-,Bcl 6-,Bcl 2-, CD21-, CD30-, and a hyper expression of p53 in less than 5%. 
Lymphoma
Background:
Although anthracycline-based induction chemotherapy produces high rate complete remission in patients with diffuse aggressive non-Hodgkin lymphoma (NHL), majority of the patients relapse and require high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). The optimal conditioning regimen for HSCT, has still to be determined. Patients: Between 1999 and 2004, relapsed 28 patients who underwent autologous stem cell transplantation were evaluated. The high dose regimens were ICE (Ifosfamid 2.5 gr/m²/day, 1-4. days; Etoposide 600 mg/m²/day, 1-4 days; Carboplatin 500 mg/m²/day 1-3 days), CNV (Cyclophosphamide 2.4gr/m²/day, 1. day; Mitoxantrone 40 mg/m²/day 1. day; Etoposide 200 mg/m²/day, 1. day), and BEAM (BCNU 300 mg/m²/day, 1. day; Etoposide 200 mg/m²/day, 2-5.days; ARA-C 100 mg/m2 2-5. days, Melphalane 140 mg/m²/day, 6. day). The three groups were similar on the basis of their age, gender, time from diagnosis to transplant and the disease status at the time of transplantation. They were 14 males and 11 females, and ages from 18 to 62 years (median age 42 yrs). Results: After transplantation 18 patients achived a CR and 5 a PR. Eight patients received further mediastinal RT even if they had a minimal (<25%) residual mass at computed tomography scan. The patients were evaluated according to engraftment status, toxicity, transplant-related mortality and short term response. The engraftment kinetics were similar in three regimens. The gastrointestinal toxicity has been leading in all three regimens and renal toxicity was observed only in ICE. One patient died from ICE induced transplant related mortality. We didn't find any significant difference between the conditioning regimens in terms of EFS and OS. Conclusions: We concluded that there are no difference among three conventional regimens in terms of therapeutic effects, but ICE regimens were more toxic than others. More effective and less toxic new conditioning regimens must be developed. High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (APBSCT) is accepted as the standard therapy in management of relapsed or refractory NHL to achieve long term survival. In this study, 12 patients with relapsed/refractory/high risk B-cell NHL with a median age of 41 years (M:F=10:2) were treated with high dose sequential chemotherapy (HDSC) and APBSCT. In patients with relapsed or refractory disease, HDSC/APBSCT was done in those with chemosensitive disease following 2 to 3 cycles of salvage therapy. The therapy consisted of 5 phases. Phase I consisted of immunotherapy with rituximab to consolidate the salvage therapy; phase II consisted of stem cell mobilization with cyclophosphamide (4.5 g/m²) followed by G-CSF (10 mcg/kg/d) and in vivo purging with rituximab. Phase III consisted of etoposide (2 g/m²) with G-CSF support of at 5 mcg/kg/d. The transplant phase consisted of mitoxantrone (60 mg/m²) and melphalan (180 mg/m²) followed by APBSC infusion. In phase V, two consolidation doses of rituximab were administered to treat minimal residual disease.Patients had diffuse large cell (n=5), mantle cell (n=2), small lymphocytic (n=1), follicular (n=2), Burkitt (n=1) and lymphoblastic (n=1) histology. The rationale for PBSCT was refractory (n=5) or relapsed disease (n=5), except for the 2 patients with high grade NHL in which first-line PBSCT was done because of high risk disease. Prior to HDSC, 5 patients were in CR and 7 patients were in PR. Mobilization failure which was thought to be related to previous fludarabine exposure was observed in one patient, in whom a second collection with G-CSF was successful. Patients received a median of 5.1x106/kg CD34+ cells. Median times to achieve myeloid engraftment were 17 days, with a transplant related mortality rate of 0%. One patient developed mild congestive heart failure, mainly due to high cumulative doses of anthracycline during his previous therapies. After a mean follow-up of 18 months, 83% of the patients were alive, 80% with CR. One patient died due to refractory disease and one patient with congestive heart failure died due to sudden cardiac death. The estimated 3-year overall survival was 89%.
R1250
In conclusion, HDSC and in vivo purging with rituximab followed by APBSCT is an effective and tolerable therapy in patients with relapsed/refractory and high risk NHL. Transforming growth factor -beta (TGF-beta) influences B cell growth and development. The present study aimed to determine whether there is an association between the polymorphic features located within the TGF-beta gene in NHL patients and progression the disease. Two single nucleotide polymorphisms at positions 869 T/C (Leu10Pro) and 915 G/C (Arg25Pro) polymorphisms in the precursor region of the TGF-beta gene were determined by PCR-SSP technique using commercial primers. In univariate analysis the presence of TGF-beta high producer genotypes (T/T G/G or T/C G/G) was found to significantly associate with an increased number of extranodal sites (11/30 vs 3/25, p=0.035 for 2 or more extranodal sites in patients having and lacking the TGF-beta high producer genotype). TGF-beta high producer genotype together with other clinical and biological factors (patient sex and age, stage and aggressiveness of the disease, presence of B symptoms, serum LDH level) were subjected to multivariate logistic regression analyses for the number of extranodal sites. Multivariate analysis confirmed the role of TGF-beta high producer genotype as a risk factor of NHL manifestation in 2 or more extranodal sites (OR=7.217, p=0.028) in addition to histological aggressiveness of the disease (OR=4.302, p=0.057). TGF-beta genotype was not found to affect the survival. TGF-beta gene polymorphisms were found to associate with the course of the disease in NHL patients. TGF-beta high producer genotype appeared as independent risk factor of enhanced extranodal manifestation of the disease.
R1252 Patients with follicular lymphoma relapsing after ASCT treated by rituximab monotherapy O. Krieger, H. Greinix, H. Kasparu, M. Mitterbauer, U. Jaeger, D. Lutz Elisabethinen Hospital (Linz, A); University Hospital (Vienna, A)
Twelve patients with follicular lymphoma (FCL), relapsing more than 6 months after autologous stemcell-transplantation (ASCT), received rituximab (375mg/m²) weekly as post transplant induction therapy in a multicenter phase IV trial. After completion of fourth cycle patients entered an observation period. Results: 12 patients ( 9 male, 3 female ), 28-61 years old (median: 48,5) were treated. Median time from diagnosis to ASCT was 30 months (range: 9-65) and median time from ASCT to rituximab 18 months (range 6-52). Treatment was well tolerated, in 4/48 therapy cycles grade III-IV toxicity ( 2 FUO, 1 bronchopulmonary infection, 1 chills+pain ) was observed only. No delayed granulocytopenia occurred. 8/12 (66%) patients responded within 4 weeks -5 CR, 3 PR -, whereas 4 patients were refractory to rituximab (NC): 2/4 NC died within 1 month, one patient was treated with chemotherapy and lives in PR for 23 months; 1 NC-patient was transplanted (RIC-alloSCT) 4 months after rituximab and is alive in CCR for 54 months. 3/8 responders relapsed and died after 20, 43 and 44 months despite treatment was continued with chemotherapy. 5 patients are alive (4 in CCR -2 after RIC-alloSCT,1 in PR) 18, 24, 29 and 46 months after initiating rituximab. Conclusion: Rituximab is effective and a safe therapy for patients with FCL relapsing after ASCT with a 66% response rate. But to achieve a continuous complete remission additional chemotherapy or RIC-alloSCT was needed in one third of our patients.
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Autologous peripheral blood stem cell transplantation with interferon alfa as a maintenance in patients with Burkitt-like lymphoma M. Cioch, A. Walter-Croneck, M. Podhorecka, D. Jawniak, M. Wach, W. Legiec, A. Dmoszynska Medical University (Lublin, PL) Burkitt-like lymphoma (BLL) is very agressive B-cell malignancy characterized by a rapid clinical course and poor outcome. Recently, intensive chemotherapy followed by autologous peripheral blood stem cell transplantation (APBSCT) has improved results of therapy and may lead to cure in selected patients (pts). We retrospectively analyzed outcome of 8 pts (3 M/5F with median age: 38.6, range: 23-55) with BLL undergoing APBSCT in 1999 APBSCT in -2004 . Before transplantation pts received CHOP (6 pts), CODOX-M (1 pt), and mBACOD (1 pt). Mobilization was performed after cyclophosphamide (6 pts) or 1-2 courses of DHAP (2 pts). The conditioning regimen was BEAM in 7 pts and high-dose melphalan (200 mg/m²) in 1 pt. Disease status at transplantation was CR in 7 pts; one pt had residual mediastinal lymphoma masses. The mean number of CD34 positive cells reinfused was: 3.29x10 6 /kg (range: 2.26 -5.54). G-CSF at a dose 5-10 µg/kg daily was administered following transplantation until neutrophil count reached 0.5x10 9 /l. All pts had neutropenia and thrombocytopenia in grade IV acc. WHO grading. Median number of days for neutrophil recovery to more than 0.5x10 9 /l was 13 (range:10 -42) Number 50.0 x 10 9 /l of plateles was reached before 50 days by none of pts. Mucositis was the most frequent complication observed in this group of pts. Due to this esophagostenosis was developed in one pt. After stable angrafment one pt with mediastinal changes observed before transplantation received radiation therapy and all pts were receiving maintenance therapy with interferon alpha (3 mln IU three times weekly) for 6 months. Until now all pts are alive and all are in CR. An overall survival (OS) of transplanted pts is mean 35.1 months, median 36.5 (range: 6 -63); event free survival (EFS) is mean 26.3 months, median 28 (range: 15 -49) . This a single-centre experience shows that APBSCT with interferon alfa as a maintenance is one of the best therapeutical option available for pts with BLL, especially compared with results of standard chemotherapy (OS 5-8 months).
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Rituximab plus ICE as second-line treatment for relapsed and refractory aggressive non-Hodgkin lymphomas I. Panovska-Stavridis, B. Georgievski, L. Cevreska, Z. Stojanovski, A. Pivkova, S. Krstevska-Balkanov, N. Siljanovski Clinical Centre (Skopje, MK) Background: High-dose chemotherapy (HDT) or radiotherapy followed by autologous or allogeneic stem cell transplantation (SCT)is a potentially curative treatment approach for patient with relapsed and refractory aggressive Non-Hodgkin lymphomas (NHL). However, its applicability is restricted to patient responding to second line treatment (SLT). To date, there has been no SLT regimen that has proven to be superior with regard to response rate and to stem cell toxicity. Aims: To evaluate the effects of Rituximab added to SLT regimen (ICE) in relapsed and refractory aggressive NonHodgkin lymphomas. Methods: We report our initial results of a SLT regimen consisting of Rituximab and ICE(R-ICE) in the first 9 evaluable patients, previously treated with a single standard antracycline-containing regimen for aggressive lymphomas at the Clinic of Hematology, Medical Faculty-Skopje. Patients diagnosed as CD20+ aggressive B-NHL, with the median age 47.4 (range 29-62) were either in first relapse (6 patients) or refractory to treatment (3 patients). Patients received Rituximab 375/m² on day (d) 1,Etoposide 100 mg/m² d 3-5; Ifosfamide 5g/m²/ d4 mixed with the equal dose of MESNA and Carboplatin at AUC 5 d4, repeated every 14 days for a total of 3 cycles. Leukapheresis was performed after the third cycle. Results: The median duration of treatment was 41day (range 35-52). The regimen was very well tolerated and no serious side-effects were observed. The overall response rate was 75% (6 patients) with 50% (4 patients) in complete remission. A median of 4.4 millions CD34+cells/kg were collected in a median of 2 apheresis (range 1-4) and all patients were eligible for HDT/SCT. Conclusion: Our initial results suggest that R-ICE regimen is a very effective for cytoreduction and mobilization in patients with relapsed and refractory aggressive NHL and support the thesis that the addition of Rituximab to chemotherapy significantly enhances the response rate in NHL patients presumably as a result of the synergistic effects of the Rituximab with standard SLT regimens.
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Sequential high-dose chemotherapy plus autograft in refractory Hodgkin's disease patients O. Karanfilski, A. Stojanovic, L. Cevreska, A. Pivkova, Z. Stojanoski, S. Trajkova, S. Krstevska-Balkanov, B. Georgievski Clinical Center (Skopje, MK) Among almost 100 transplants performed at our Department, we have treated a total of six HD patients according to the German protocol until now, three male and three female. Their age varied from 21 to 42. Indications for using this approach were: multiple relapses in two cases, quick relapse after initial treatment (<12 months) in one, and initial treatment failure with disease progression in three. Transplants consisted of harvested peripheral stem cells in five cases and in one patient a combined graft (PBSC + BM) was administered, due to insufficient quantity of peripheral cells harvested. In all six patients, marked response to treatment was observed, resulting in tumor mass reduction and symptom loss, i.e. in disease control. In three patients residual tumor mass was noted after completion of the procedure, for which additional involved site radiotherapy was performed. Following protocol cessation, progression of disease was observed in two patients so far, following 6 and 28 months of disease-free period. One patient was treated with salvage chemotherapy intermittently and radiotherapy, until the fatal outcome (cardiovascular complications), one year after autografting. The other is currently under salvage chemotherapy, The other four patients are in a stable state, without disease progression, 3-14 months after completion of the procedure. Problems encountered in the procedure consisted most often of profound leuko-and thrombocytopenia, managed fairly easily by adequate substitution and stimulation therapy; still, these complications are accountable for prolonging the time schedule of the protocol in some instances. Due to previous bone marrow ''exhaustion'' PBSC harvests often resulted in low cell yield, thus requiring more sessions or alternative methods. Infective and hemorrhagic complications were extremely rare and managed with standard counter-measures. Three of the patients received Epo complimentary to the protocol, thus diminishing erythrocyte transfusion requirements. In one patient toxic affection of the liver was noted during the sequential HDCT course, requiring hepatoprotective treatment and postponement of the procedure. Our initial impressions from implementing the GHLSG protocol in the management of poor prognosis, previously treated, HD patients, are certainly positive. We exercise progressively greater latitude in decreasing the proportional in-hospital stay, one of the requirements quite uncomfortable to the patients.
Multiple myeloma
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Maintenance with low-dose thalidomide after autoSCT in multiple myeloma L. Pezzullo, S. Rocco, O. Finizio, L. Bene, B. Casale, C. De Rosa, V. Mettivier A.O.R.N. A. Cardarelli (Naples, I) High dose therapy with single or double transplantation (auto-SCT) has improved prognosis of multiple myeloma (MM). New drugs are promising in upfront therapy while the role of maintenance is still debated. Thalidomide (thal) is an active drug in the treatment of myeloma, and is been investigated as first line therapy. It could be useful in the control of minimal residual disease. We used thal as maintenance after autologous transplantation (single or double) and compare the outcome with other maintenance or none. From January 2001 to June 2004 20 patients (10 males and 10 females) with MM have been treated in our institution. Median age was 58 years (range 51-72). 9 were IgG, 6 IgA, 2 light chains and 2 plasma-cell leukaemia. Treatment was 4 cycles of VAD regimen followed by auto-SCT. 10/20 performed double auto-SCT. 3 months after SCT, 10 patients (5 single and 5 double SCT) began thal 50 mg/die as maintenance therapy. 10 patients (5 single and 5 double SCT) received IFN-g (3/10), dexa (3/10) or no therapy (4/10). The 2 groups were regarding the type of myeloma: 5 IgG, 2 IgA, 2 light chains and 1 plasma-cell leukaemia the thal group; 4 IgG, 4 IgA, 1 IgD and 1 plasmacell leukaemia the other. Response to SCT: 2 CR and 8 PR in the thal group; 5 CR, 4 PR and 1 NR in the other. In the thal group only 1/10 patient relapsed (plasma-cell leukaemia) after suspension of thal. Median follow up from the beginning of maintenance therapy was 25.8 months (range 7-30) with 9/10 patients in CR or stable disease, with a progression free survival (PFS) and overall survival (OS) projected at 30 months of 83%. In the other group, 8/10 patients relapsed. Median follow up was 35 months (range 5-46) with a PFS of 15% and OS of 47%. The difference between the 2 groups is statistically significant for PFS (p: 0,003), and not significant for OS (p: 0,13) even if difference (83% vs. 47%) appears clear. (Tab.1-2) Thal was administered for a median period of 6 months, being neurological toxicity the main reason of suspension (3/10 patients). Neurological toxicity grade I-III was present in 65% of patients, while haematological toxicity grade I occur in 55% of patients. In conclusion, in a small number of patients low dose thal as maintenance after auto-SCT resulted in an improved PFS and OS when compared with other or none maintenance, with acceptable toxicity. Further studies in larger cohorts and randomized trials are needed to confirm this experience.
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Planned sequential autologous / non-myeloablative allogeneic peripheral stem cell transplantation in patients with newly diagnosed high-risk multiple myeloma W. Zinke-Cerwenka, P. Neumeister, M. Eibl, H. Sill, W. Emberger, T. Wagner, A. Wölfler, W. Linkesch Medical University (Graz, A) Background: ASCT with subsequent nonmyeloablative (N) allogeneic SCT is an attempt to reduce the tumor burden through autograft and eradicate residual disease through the graft versus myeloma effect of donor cells with the advantage of less toxicity. Patients and methods: Six patients (five female, one male; ages between 35 and 57 years) with newly diagnosed MM underwent the autologous/ nonmyeloablative allogeneic tandem procedure. All of them showed high-risk disease, in three cases based on the presence of FISH-defined chromosome 13 deletions. Single ASCT with mephalan 200 mg/m² for cytoreduction was performed within 3 months after the last chemotherapy followed by nonmyeloablative allogeneic SCT between 3 and 4 months later. Disease status showed PR in five patients and CR in one patient before the second transplantation. The conditioning regimen consisted of intravenous fludarabine 30mg/m² on days -4,-3, and -2 and melphalan 100mg/m² on day -1. Five patients received unmanipulated peripheral stem cells from their HLA-identical siblings, one patient from an unrelated donor with c-mismatch. The grafts contained a median of 6.7x10 6 CD34+ cells/kg (range 4.4-7.68) and 2.5x10 8 CD3+ cells/kg (range 1.4-2.6). GVHD prophylaxis consisted of Cyclosporine and Mycophenolate mofetil. The patient with the unrelated donor received additionally ATG(5mg/kg, days -4 to -1). Results: There was no TRM until +100. ANC greater than 0.5x10 9 /L occurred at a median of 13 days (range 12-16). Four patients did not require any platelet or RBC transfusions. One patient received three platelet transfusions due to a platelet count lower than 20 x 10 9 /L and two units of RBCs, another patient was transfused with 4 units of RBCs. All patients achieved complete donor chimerism by day 28. One patient developed severe acute GVHD (grade IV). Extensive chronic GVHD was seen in another patient. After a median follow-up of 287 days (range 214-442) after NSCT 5 of 6 patients are alive. Status of disease at evaluation in November 2004 showed 3 patients with CR and 2 with nearly CR (nCR: CR with only positive immunofixation). One patient died on day +210 in nCR due to new developed refractory cardiac arrhythmia.
Conclusions: We could demonstrate in patients with newly diagnosted high-risk myeloma that the strategy of a single ASCT to reduce tumor burden followed by allogeneic NSCT leads to a rapid and sustained engraftment and complete donor chimerism on day 28 with tolerable toxicity.
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Bortezomib as salvage therapy in patients with relapse of multiple myeloma after allogeneic haematopoietic cell transplantation U. Hegenbart, S. Schonland, M. Munder, J. Perz, G. Egerer, H. Goldschmidt, A. Ho University of Heidelberg (Heidelberg, D) Allogeneic hematopoietic cell transplantation (HCT) is an important treatment option for patients (pts) with multiple myeloma (MM). By using reduced-intensity conditioning regimens and more frequent recruitment of unrelated donors, the number of allogeneic HCTs in MM has been increasing over the last years. Long-lasting remissions have been reported in about 20-40% of pts, depending on previous disease course, several biological risk factors, and disease status at time of HCT. The rate of disease relapse or progression after allogeneic HCT is high and treatment options such as withdrawal of immunosuppressive therapy +/-chemotherapy, donor lymphocyte infusions (DLI), radiotherapy and thalidomide (Thal) are needed. Only in some of these patients sustained remissions were observed. Bortezomib (BOR) is a new treatment option for patients who relapse after allogeneic HCT, are not eligible for DLI and have been refractory to the therapy mentioned above. We report on 7 pts (age 46 -63 years) who relapsed post allogeneic HCT after a median of 218 (range 100-1372) days. Pts had been transplanted (donors: 5 pts related, 2 pts unrelated) after conditioning with 2 Gray (Gy) total body irradiation/fludarabine (n=5), fludarabine/melphalan/campath (n=1) or melphalan (n=1). Treatment of relapse included withdrawal of immunosuppressive therapy, DLI, chemotherapy, pulsed dexamethasone and Thal. As none of the patients had responded, treatment with BOR was started in a standard dosage. Until date of last analysis (15/11/04), a median of 3 treatment cycles was applied (range 1-9). Best responses were PR in 3 pts, SD in 3 pts and progression of an extramedullary tumor in 1 pt. In those 3 pts who progressed after BOR, remission had lasted 3, 12 and 14 months. Two pts relapsed while receiving BOR maintenance therapy, 1 pt. responded again after intensification of BOR administration. Non-hematological toxicity included mucositis grade 2 in 2 pts and grade 3 in 1 pt, pneumonia in 1 pt, and neutropenic fever in 1 pt. Dose reductions due to hematological toxicity were necessary in 5 out of 7 patients. BOR shows encouraging anti-myeloma activity in pts who relapse after allogeneic HCT. Treatment of relapses after allogeneic HCT will be an important issue in the future. A therapeutic alghorithmus is necessary to find the best individual treatment which may include additionally to DLI the new substances such as BOR and lenalidomide.
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Evaluation of 72 autologous transplantations in 46 patients with multiple myeloma I. Markuljak, J. Banakova, E. Kralikova, B. Wildova, A. Wild, H. Genserkova, J. Hudec, I. Rudolfova, S. Olvecka, R. Alberty, M. Zarnovicanova F.D.Roosevelt Hospital (Banska Bystrica, SVK) Background: High dose therapy (HDT) with autologous stem cell transplantation (ASCT) has been increasingly used in the past 15 years in multiple myeloma (MM). It has been shown by several studies that ASCT is safe and effective therapy with less than 5% transplant related mortality (TRM) and prolongation of OS (overall survival) in comparism with conventional chemotherapy (CC 2 ) + G-CSF (5-10ug/kg) priming until at least (if it was possible) 2 x10 6 /kg CD34+ cells were collected, with median number of aphereses 1 (1-4). The source of SC was peripheral blood in all cases. Results: CR after CC before ASCT was reached in 6,52% (3 pts) and after ASCT (single+double) in 30,4% (14 pts) and 65,25% reached PR. TRM was observed in 2 pts ( 2,78 %) (1 died of pneumonia and one of fatal arrhythmia). Median number of CD34+ cells harvested was 5,86 (0,53-46,66) x 10 6 /kg and infused 3,50 (0,53-23,93) x10 6 /kg. All pts engrafted. The median time to recovery of leukocytes (>1 x10 9 /l) and platelets (>20 x10 9 /l) was reached on day +10 (8-16) and on day +11 (9-25) respectively. The major complication after ASCT was mucositis gr. 3-4 in about one third of pts. Median OS was 40 months and EFS 16. Median OS after double ASCT was better than after single ASCT but not signficantly (51 [n=9] months vs 40 [n=17], p=0,238). Conclusion: We conclude that ASCT in MM is safe and effective procedure we confirm results of previous studies regarding CR rate, successfull and fast engraftment if sufficient number of CD34+ cells is infused, low TRM. OS and EFS were not as good as we would expect, probably because of small cohort of patients evaluated, some of them with more advanced disease and heavily pretreated before ASCT. Such pts were transplated during the first years of our transplant programme. And also longer follow-up is required to get more precise results.
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Treatment of multiple myeloma with autologous stem cell transplantation: a single-centre experience M. Wach, M. Cioch, M. Malek, W. Legiec, A. Walter-Croneck, J. Manko, M. Gorska, K. Zapalska, A. Dmoszynska University School of Medicine (Lublin, PL) Patients with multiple myeloma (MM) treated with conventional chemotherapy have a median survival of approximately 3 years. High dose chemotherapy followed by autologous peripheral stem cell transplantation (ASCT) is now considered as the standard therapy for almost all patients with multiple myeloma. From November 1997 to October 2004, 76 patients with MM ( 31 females, 45 males, median age -50 year (±8,10) range: 30-66 y) were transplanted in our Department. 45 patients were in first complete remission, 23 patients were in partial remission, 4 was in SD, 4 out of them were without any treatment. Among them there were 61 with IgG myeloma, 13
